Imunon, Inc. Increase (Decrease) in Other Current Assets
Imunon, Inc. (IMNN) reported Increase (Decrease) in Other Current Assets of -$115.86 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-08-11
- Imunon, Inc. increase (decrease) in other current assets for the quarter ending 2026-06-30 was $10.00.
- Imunon, Inc. increase (decrease) in other current assets for the quarter ending 2026-03-31 was -$115.87K, a 237.93% decline year-over-year.
- Imunon, Inc. increase (decrease) in other current assets for the quarter ending 2025-12-31 was -$64.07K.
- Imunon, Inc. increase (decrease) in other current assets for the quarter ending 2025-09-30 was -$155.71K.
- Imunon, Inc. increase (decrease) in other current assets for fiscal 2025 was -$193.51K.
- Imunon, Inc. increase (decrease) in other current assets for fiscal 2024 was -$408.86K, a 388.70% decline from fiscal 2023.
- Imunon, Inc. increase (decrease) in other current assets for fiscal 2023 was $141.62K.
- Imunon, Inc. increase (decrease) in other current assets for fiscal 2021 was $124.73K.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$115.86K 10-Q · filed 2026-08-11 | -$179.93K derived: sum of 3 quarters · filed 2026-08-11 | -$335.64K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$115.87K 10-Q · filed 2026-05-12 | -$179.94K derived: sum of 2 quarters · filed 2026-05-12 | -$335.65K derived: sum of 3 quarters · filed 2026-05-12 | -$393.38K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$64.07K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$219.78K derived: sum of 2 quarters · filed 2026-03-31 | -$277.51K derived: sum of 3 quarters · filed 2026-08-11 | -$193.51K 10-K · filed 2026-03-31 |
| 2025-09-30 | -$155.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$213.44K derived: sum of 2 quarters · filed 2026-08-11 | -$129.44K 10-Q · filed 2025-11-13 | -$213.72K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$57.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $26.28K 10-Q · filed 2026-08-11 | -$58.00K derived: sum of 3 quarters · filed 2026-08-11 | -$177.30K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $84.01K 10-Q · filed 2026-05-12 | -$271.00 derived: sum of 2 quarters · filed 2026-05-12 | -$119.57K derived: sum of 3 quarters · filed 2026-05-12 | -$65.29K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$84.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$203.58K derived: sum of 2 quarters · filed 2026-03-31 | -$149.30K derived: sum of 3 quarters · filed 2026-03-31 | -$408.86K 10-K · filed 2026-03-31 |
| 2024-09-30 | -$119.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$65.02K derived: sum of 2 quarters · filed 2025-11-13 | -$324.58K 10-Q · filed 2025-11-13 | -$47.44K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $54.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$205.28K 10-Q · filed 2025-08-05 | $71.86K derived: sum of 3 quarters · filed 2025-08-05 | $74.69K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$259.56K 10-Q · filed 2025-05-12 | $17.57K derived: sum of 2 quarters · filed 2025-05-12 | $20.41K derived: sum of 3 quarters · filed 2025-05-12 | -$129.15K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $277.14K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $279.97K derived: sum of 2 quarters · filed 2025-02-27 | $130.41K derived: sum of 3 quarters · filed 2025-02-27 | $141.62K 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.83K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$146.72K derived: sum of 2 quarters · filed 2024-11-07 | -$135.52K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$149.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$138.35K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $11.20K 10-Q · filed 2024-05-13 | |||
| 2022-09-30 | $78.22K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $300.90K derived: sum of 2 quarters · filed 2023-11-14 | $273.65K 10-Q · filed 2023-11-14 | -$154.19K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $222.69K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $195.43K 10-Q · filed 2023-08-10 | -$232.41K derived: sum of 3 quarters · filed 2023-08-10 | $136.40K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$27.26K 10-Q · filed 2023-05-11 | -$455.10K derived: sum of 2 quarters · filed 2023-05-11 | -$86.28K derived: sum of 3 quarters · filed 2023-05-11 | $114.97K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$427.84K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$59.03K derived: sum of 2 quarters · filed 2022-11-14 | $142.23K derived: sum of 3 quarters · filed 2022-11-14 | $124.73K 10-K · filed 2022-03-31 |
| 2021-09-30 | $368.81K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $570.07K derived: sum of 2 quarters · filed 2022-11-14 | $552.57K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $201.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $183.76K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | -$17.50K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | -$274.51K 10-K · filed 2022-03-31 | |||
| 2019-12-31 | $74.34K 10-K · filed 2021-03-19 | |||
| 2018-12-31 | $250.17K 10-K · filed 2020-03-25 | |||
| 2017-12-31 | -$115.22K 10-K · filed 2018-03-27 | |||
| 2016-12-31 | $14.86K 10-K · filed 2018-03-27 | |||
| 2015-12-31 | -$246.40K 10-K · filed 2017-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |